Sulfonylureas may increase risk of death in type 2 diabetes patients

09/26/2013 | U.S. News & World Report

British researchers found type 2 diabetes patients who used sulfonylureas as an initial treatment had a 58% higher risk of all-cause mortality compared with those who were on metformin monotherapy. While more data are needed, the results suggest using sulfonylureas as first-line monotherapy "should be reconsidered," researchers reported at the European Association for the Study of Diabetes meeting.

View Full Article in:

U.S. News & World Report

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC